REQUEST FOR ICD-10-CM CODE FOR BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL)

Scot Bradley Glasberg, MD, FACS
American Society of Plastic Surgeons
September 9, 2020

AMERICAN SOCIETY OF PLASTIC SURGEONS ®

THE PLASTIC SURGERY FOUNDATION ™

DISCLOSURES

Consultant, Allergan Corp.
Consultant, Surgical Specialties Inc. (Quill)
Consultant, KCI Corp., Acelity Group
Consultant, Guidepoint Global
Consultant, Gerson Lehrman Group
Investor, Red Rock Holdings (Scar Guard)
Investor, Stockholder, Evolus Inc.

Vice President, Development, The Plastic Surgery Foundation
Past President, American Society of Plastic Surgeons
Past President, Board of Trustees, New York County Medical Society
Past President, Board of Trustees, New York Regional Society of Plastic Surgeons
Past President, Executive Council, New York State Society of Plastic Surgeons
Past Governor, American College of Surgeons
Advertising Editor, Managing Committee, Journal of Plastic and Reconstructive Surgery
Associate Editor, PRS-Global Open Access

AMERICAN SOCIETY OF PLASTIC SURGEONS ®

THE PLASTIC SURGERY FOUNDATION ™

BREAST IMPLANT STATISTICS

- Approximately 400,000 implant procedures per year in the US
  - 299,715 cosmetic
  - 88,005 reconstructive

- Incidence range for BIA-ALCL is between 1 in every 2,207 – 86,029 women

AMERICAN SOCIETY OF PLASTIC SURGEONS ®

THE PLASTIC SURGERY FOUNDATION ™

BIA-ALCL PRESENTATION/CHARACTERISTICS

Typically presents as swelling of the breast

- 79% of patients have seroma
- 74% have capsular contracture
- 13% have palpable mass

Also noted: breast asymmetry, pain, skin rash, enlarged lymph nodes, fever, weight loss

BIA-ALCL is not a disease of the lymph nodes nor the breast tissue but is instead a disease of the capsule surrounding a breast implant

BIA-ALCL PRESENTATION/CHARACTERISTICS

Age

- Median Age 54
- Range 28 to 84

- Time from current implant to BIA-ALCL diagnosis
  - Median 9 years
  - Range 0.8-27 years

Source: ASPS/PSF Profile Registry
August 23, 2020

AMERICAN SOCIETY OF PLASTIC SURGEONS ®

THE PLASTIC SURGERY FOUNDATION ™

BIA-ALCL DIAGNOSIS

- Needle aspiration with testing of fluid
  - Testing for CD-30 required to confirm diagnosis
  - Anaplastic lymphoma kinase (ALK)
    - For BIA-ALCL: CD-30 + / ALK -
- Imaging
  - PET scan
- Surgery to remove capsule/scar tissue and implant
  - Masses and lymph nodes removed
  - Consideration of chemotherapy/radiation treatment
- Regular screening to ensure remission

SUMMARY

Pathologically BIA-ALCL is distinct from systemic ALCL

- Recognized by the National Comprehensive Cancer Network (NCCN), and National Cancer Institute (NCI) as a unique disease.
- Requires a multidisciplinary team approach for each patient

AMERICAN SOCIETY OF PLASTIC SURGEONS ®

THE PLASTIC SURGERY FOUNDATION ™

WHY A UNIQUE CODE?

Statistical information captured via a unique ICD-10-CM code will:

- Help promote data collection and analysis
- Improve public health surveillance of BIA-ALCL in the United States and globally.

AMERICAN SOCIETY OF PLASTIC SURGEONS ®

THE PLASTIC SURGERY FOUNDATION ™

ASPS APPRECIATES THE OPPORTUNITY TO PRESENT THIS PROPOSAL TO THE CDC CMS COMMITTEE

Questions?

AMERICAN SOCIETY OF PLASTIC SURGEONS ®

THE PLASTIC SURGERY FOUNDATION ™